Glucagonoma is a rare endocrine tumor process characterized by hypersecretion of glucagon, which leads to the development of various metabolic disorders. Most cases of glucagonoma are associated with the presence of a tumor in the alpha cells of the pancreas. The hormone produced by glucagon promotes an increase in blood glucose levels due to gluconeogenesis and glycogenolysis, which ultimately leads to the development of hyperglycemia. The clinical picture of the disease often includes symptoms associated with insulin deficiency and increased catabolic processes, which can manifest as weight loss, skin rash, and neuropathy. Glucagonoma is usually diagnosed in patients aged 50–70 years, but cases occur at earlier and later ages.
History of the disease and interesting historical facts
Glucagonoma was first described in the mid-20th century. One of the first studies regarding this type of tumor was a case report in 1965, where surgeons removed glucagonoma from a patient’s pancreas for the first time. Since then, there have been many studies focusing on the pathophysiology, diagnosis, and treatment of glucagonoma. Interestingly, advancements in medical technology have made it possible to more accurately identify glucagonomas and differentiate them from other endocrine disorders. Statistical studies show that such tumors are predicted to occur in less than 1% of all pancreatic tumors, confirming their rarity.
Epidemiology
According to statistics, glucagonoma is observed in one in 20,000–50,000 of the population. Epidemiological studies show that this disease is more common in men and women equally. According to clinical observations, the average age of patients at the time of diagnosis is 60 years. There is also a link between the presence of multiple endocrine neoplasia (MEN) type 1 and the occurrence of glucagonoma, which indicates the possibility of a genetic predisposition to this disease.
Genetic predisposition to this disease
Some genetic mutations can increase the risk of glucagonoma. For example, pathologies in the MEN1 genes, which are associated with multiple endocrine neoplasia, can lead to the formation of glucagonoma. Studies show that patients with MEN 1 have a significantly increased risk of developing exocrine and endocrine tumors. Mutations in the TP53 and CDKN2A genes, which can interfere with cell cycle regulation and increase the likelihood of malignant growth, are also important markers.
Risk factors for the development of this disease
There are several factors that contribute to the development of glucagonoma, including:
- Age: Most cases occur in people over 50 years of age.
- Family history: Having relatives with endocrine tumors may increase the risk.
- Multiple endocrine neoplasia (MEN) type 1.
- Chronic diseases of the pancreas, such as pancreatitis.
- Excessive alcohol consumption and smoking.
Diagnosis of this disease
Diagnosis of glucagonoma is based on the clinical picture and a number of laboratory and instrumental studies:
- The main symptoms include hyperglycemia, weight loss, dermatological problems and digestive disturbances.
- Laboratory tests: Plasma glucagon levels exceed 500 pg/ml, which is the criterion for diagnosis.
- Radiological examinations: CT and MRI allow visualization of pancreatic tumors and their metastases.
- Other types of diagnostics: endoscopic ultrasonography and biopsy if suspicious formations are detected.
- Differential diagnosis must be made with insulinomas and other endocrine tumors.
Treatment
Treatment for glucagonoma may vary depending on the stage of the disease and the patient's conditions:
- General treatment includes supportive therapy aimed at lowering blood glucose levels.
- Pharmacological treatment: use of insulin analyzers, diet and drugs that help improve insulin sensitivity.
- Surgical treatment: Resection of the tumor, if possible, significantly increases the chances of recovery.
- Other treatments: Chemotherapy may be considered for metastatic forms of the disease.
List of medications used to treat this disease
- Dextrose solutions for the correction of hypoglycemia.
- End-to-end insulin modulators for glycemic control.
- Ppalestin is a drug that maintains glucose levels.
Disease monitoring
Monitoring of glucagonoma involves regular testing of blood glucagon levels and examinations to monitor the progression of the disease:
- Control stages: every 3–6 months after completion of therapy.
- Prognosis: With adequate treatment and early diagnosis, survival rates improve significantly.
- Complications: Metastases to the liver and other organs can worsen the prognosis.
Age-related features of the disease
Glucagonoma may manifest itself differently depending on the age category of patients:
- In older patients, the tumor is often more aggressive.
- Young people are usually diagnosed with relatively benign forms of the disease that require observation.
- Clinical manifestations can also vary significantly depending on age group, which makes early diagnosis difficult.
Questions and Answers
- What are the main symptoms of glucagonoma? The main symptoms include weight loss, hyperglycemia, skin rashes and osteopathies.
- How is glucagonoma diagnosed? Diagnosis is based on glucagon level analysis, CT scan and biopsy.
- What is the treatment for glucagonoma? Treatment may be surgical, pharmacological and supportive.
- What is the prognosis and risk of recurrence of the disease? The prognosis depends on the stage of the disease; with early treatment the chance of recovery is high; relapses are possible.
- We are at risk, how can we prepare for this? Regular examination and tests allow us to detect the disease at an early stage and prevent the development of serious complications.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov emphasizes the importance of regular glucose monitoring in patients with glucagonoma. The main aspect of diagnosis is a comprehensive examination of all endocrine functions of the body. It is necessary to monitor changes in weight and skin condition, as these symptoms may indicate the progression of the disease. It is recommended to adhere to a balanced diet and avoid stress, which can help stabilize the patient's condition.
